---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-011844"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:02:32.588889+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CER-1236 first-in-human data show no CRS/ICANS; platelet transfusion independence in index AML patient

## Summary
- No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.
- Index patient with inv(3) AML achieved platelet transfusion independence for 72 days after multiple CER-1236 doses.
- CER-1236 successfully manufactured for all four enrolled patients; study expanded to include MDS and myelofibrosis.
- TIM-4 ligand target expressed on AML but not healthy bone marrow; no off-tumor cytotoxicity in preclinical safety assays.

## SEC filing metadata
- accession: 0001213900-26-011844
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026011844/0001213900-26-011844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026011844/ea0275412-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-011844
- JSON: https://secwatch.observer/filing/0001213900-26-011844.json
- Plain text: https://secwatch.observer/filing/0001213900-26-011844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.